The Global Neuropathic Pain Drug Market to grow USD 13,380.73 Million by 2025, at a CAGR of 8.72%.

The Global Neuropathic Pain Drug Market is expected to grow from USD 8,098.49 Million in 2019 to USD 13,380.73 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 8.72%.

Market Segmentation & Coverage:

This research report categorizes the Neuropathic Pain Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Neuropathic Pain Drug Market studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

Based on Treatment, the Neuropathic Pain Drug Market studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type further studied across Ibuprofen and Naproxen.

Based on Indication, the Neuropathic Pain Drug Market studied across Diabetic Neuropathy and Spinal Stenosis.

Based on Diagnosis, the Neuropathic Pain Drug Market studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination further studied across CT, Electromyography, and MRI.

Based on Distribution, the Neuropathic Pain Drug Market studied across Online Pharmacies and Retail Pharmacies & Drug Stores.

Based on End User, the Neuropathic Pain Drug Market studied across Clinics and Hospitals.

Based on Geography, the Neuropathic Pain Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuropathic Pain Drug Market including Baxter Healthcare Corporation, Biogen Idec Inc., Bristol-Myers Squibb and Company, Depomed Inc., Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., and Sanofi S.A..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neuropathic Pain Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathic Pain Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathic Pain Drug Market?

4. What is the competitive strategic window for opportunities in the Global Neuropathic Pain Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Neuropathic Pain Drug Market?

6. What are the modes and strategic moves considered suitable for entering the Global Neuropathic Pain Drug Market?

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Stakeholders

2.1. Research Process

2.1.1. Define: Research Objective

2.1.2. Determine: Research Design

2.1.3. Prepare: Research Instrument

2.1.4. Collect: Data Source

2.1.5. Analyze: Data Interpretation

2.1.6. Formulate: Data Verification

2.1.7. Publish: Research Report

2.1.8. Repeat: Report Update

2.2. Research Execution

2.2.1. Initiation: Research Process

2.2.2. Planning: Develop Research Plan

2.2.3. Execution: Conduct Research

2.2.4. Verification: Finding & Analysis

2.2.5. Publication: Research Report

2.3. Research Outcome

3.1. Market Outlook

3.2. Type Outlook

3.3. Treatment Outlook

3.4. Indication Outlook

3.5. Diagnosis Outlook

3.6. Distribution Outlook

3.7. End User Outlook

3.8. Geography Outlook

3.9. Competitor Outlook

4.1. Introduction

5.1. Introduction

5.2. Drivers

5.3. Restraints

5.4. Opportunities

5.5. Challenges

6.1. Porters Five Forces Analysis

6.1.1. Threat of New Entrants

6.1.2. Threat of Substitutes

6.1.3. Bargaining Power of Customers

6.1.4. Bargaining Power of Suppliers

6.1.5. Industry Rivalry

6.2. Cumulative Impact of COVID-19

6.3. Client Customizations

7.1. Introduction

7.2. Phantom Limb Pain

7.3. Post Herpetic Neuralgia

7.4. Post-traumatic Neuropathy

7.5. Trigeminal Neuralgia

8.1. Introduction

8.2. Antidepressant Drugs Type

8.2.1. Serotonin Noradrenaline

8.2.2. Tricyclic Antidepressants

8.3. Medication Type

8.4. Multimodal Therapy

8.5. NSAIDs Type

8.5.1. Ibuprofen

8.5.2. Naproxen

9.1. Introduction

9.2. Diabetic Neuropathy

9.3. Spinal Stenosis

10.1. Introduction

10.2. Blood Tests

10.3. Imaging Physical Examination

10.3.1. CT

10.3.2. Electromyography

10.3.3. MRI

11.1. Introduction

11.2. Online Pharmacies

11.3. Retail Pharmacies & Drug Stores

12.1. Introduction

12.2. Clinics

12.3. Hospitals

13.1. Introduction

13.2. Americas

13.2.1. Argentina

13.2.2. Brazil

13.2.3. Canada

13.2.4. Mexico

13.2.5. United States

13.3. Asia-Pacific

13.3.1. Australia

13.3.2. China

13.3.3. India

13.3.4. Indonesia

13.3.5. Japan

13.3.6. Malaysia

13.3.7. Philippines

13.3.8. South Korea

13.3.9. Thailand

13.4. Europe, Middle East & Africa

13.4.1. France

13.4.2. Germany

13.4.3. Italy

13.4.4. Netherlands

13.4.5. Qatar

13.4.6. Russia

13.4.7. Saudi Arabia

13.4.8. South Africa

13.4.9. Spain

13.4.10. United Arab Emirates

13.4.11. United Kingdom

14.1. Introduction

14.2. 360iResearch Competitive Strategic Window, by Type

14.3. 360iResearch Competitive Strategic Window, by Treatment

14.4. 360iResearch Competitive Strategic Window, by Indication

14.5. 360iResearch Competitive Strategic Window, by Diagnosis

14.6. 360iResearch Competitive Strategic Window, by Distribution

14.7. 360iResearch Competitive Strategic Window, by End User

14.8. 360iResearch Competitive Strategic Window, by Geography

15.1. 360iResearch FPNV Positioning Matrix

15.1.1. Quadrants

15.1.2. Business Strategy

15.1.3. Product Satisfaction

15.2. 360iResearch Market Ranking Analysis

15.3. 360iResearch Market Share Analysis

15.4. 360iResearch Competitive Scenario

15.4.1. Merger & Acquisition

15.4.2. Agreement, Collaboration, & Partnership

15.4.3. New Product Launch & Enhancement

15.4.4. Investment & Funding

15.4.5. Award, Recognition, & Expansion

16.1. Baxter Healthcare Corporation

16.2. Biogen Idec Inc.

16.3. Bristol-Myers Squibb and Company

16.4. Depomed Inc.

16.5. Eli Lily and Company

16.6. GlaxoSmithKline PLC

16.7. Johnson & Johnson Services Inc.

16.8. Pfizer Inc.

16.9. Sanofi S.A.

17.1. Discussion Guide

17.2. Edition Details

17.3. License Details

17.4. Pricing Details

TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2025 (USD MILLION)

TABLE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 32. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 34. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 35. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 37. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 38. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 39. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 40. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 41. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 42. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 43. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 44. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 45. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 46. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 47. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 48. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 49. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 50. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 51. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 52. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 53. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 54. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 55. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 56. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 57. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 58. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 59. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 60. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 61. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 62. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 63. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 64. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 65. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 66. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 69. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 70. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 71. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 72. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 73. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 74. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 75. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 76. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 77. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 78. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 79. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 80. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 81. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 82. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 83. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 84. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 85. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 86. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 87. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 88. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 89. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 90. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 91. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 92. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 93. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 94. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 95. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 96. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 97. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 98. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 99. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 100. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 101. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 102. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 103. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 104. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 105. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 106. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 107. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 108. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 109. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 110. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 111. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 112. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 113. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 114. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 115. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 116. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 117. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 118. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 119. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 120. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 121. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 122. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 123. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 124. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 125. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 126. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 127. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 128. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 129. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)

TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 137. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 138. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 139. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 140. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 141. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 142. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 143. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 144. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 145. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 146. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 147. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 148. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 149. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 150. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 151. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 152. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 153. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 154. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 155. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 156. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 157. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 158. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 159. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 160. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 161. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 162. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 163. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 164. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 165. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 166. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 167. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 168. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 169. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 170. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 171. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 172. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 173. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 174. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 175. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 176. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 177. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 178. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 179. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 180. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 181. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 182. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 183. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 184. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 185. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 186. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 187. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 188. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 189. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 190. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 191. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 192. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 193. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 194. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 195. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 196. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 197. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)

TABLE 198. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2017-2025 (USD MILLION)

TABLE 199. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2025 (USD MILLION)

TABLE 200. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2017-2025 (USD MILLION)

TABLE 201. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2017-2025 (USD MILLION)

TABLE 202. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2017-2025 (USD MILLION)

TABLE 203. GLOBAL NEUROPATHIC PAIN DRUG MARKET: SCORES

TABLE 204. GLOBAL NEUROPATHIC PAIN DRUG MARKET: BUSINESS STRATEGY

TABLE 205. GLOBAL NEUROPATHIC PAIN DRUG MARKET: PRODUCT SATISFACTION

TABLE 206. GLOBAL NEUROPATHIC PAIN DRUG MARKET: RANKING

TABLE 207. GLOBAL NEUROPATHIC PAIN DRUG MARKET: MERGER & ACQUISITION

TABLE 208. GLOBAL NEUROPATHIC PAIN DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 209. GLOBAL NEUROPATHIC PAIN DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 210. GLOBAL NEUROPATHIC PAIN DRUG MARKET: INVESTMENT & FUNDING

TABLE 211. GLOBAL NEUROPATHIC PAIN DRUG MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 212. GLOBAL NEUROPATHIC PAIN DRUG MARKET: EDITION DETAILS

TABLE 213. GLOBAL NEUROPATHIC PAIN DRUG MARKET: LICENSE DETAILS

TABLE 214. GLOBAL NEUROPATHIC PAIN DRUG MARKET: PRICING DETAILS